{"pmid":32374430,"title":"DC/L-SIGNs of Hope in the COVID-19 Pandemic.","text":["DC/L-SIGNs of Hope in the COVID-19 Pandemic.","In a rapidly evolving pandemic such as COVID-19, theories which help unify disparate pre-clinical and clinical observations would be useful. The current pandemic and its pleotropic effects can be explained in part by interaction between SARS-CoV-2 spike protein S, the ACE2/L-SIGN/CD209 receptor on the type II alveolar cell of the lung, and the DC-SIGN receptor on the respiratory dendritic cell (DC) and associated endothelial cells. Infection of the DC by SARS-CoV-2 can potentially explain the exuberant distal immunopathology seen in COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Brufsky, Adam","Lotze, Michael T","32374430"],"abstract":["In a rapidly evolving pandemic such as COVID-19, theories which help unify disparate pre-clinical and clinical observations would be useful. The current pandemic and its pleotropic effects can be explained in part by interaction between SARS-CoV-2 spike protein S, the ACE2/L-SIGN/CD209 receptor on the type II alveolar cell of the lung, and the DC-SIGN receptor on the respiratory dendritic cell (DC) and associated endothelial cells. Infection of the DC by SARS-CoV-2 can potentially explain the exuberant distal immunopathology seen in COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Brufsky, Adam","Lotze, Michael T"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374430","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25980","keywords":["glycoproteins","immune response","sars coronavirus"],"topics":["Mechanism"],"weight":1,"_version_":1666138496355532801,"score":9.490897,"similar":[{"pmid":32374457,"title":"The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.","text":["The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.","SARS coronavirus-2 (SARS CoV-2) is the causative agent of the Coronavirus Disease-2019 (COVID-19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after virion endocytosis. The Spike (S) glycoprotein is a major determinant of virus infectivity. Herein, we show that transient expression of the SARS CoV-2 S glycoprotein in Vero cells caused extensive cell fusion (formation of syncytia) in comparison to limited cell fusion caused by the SARS CoV S glycoprotein. Both S glycoproteins were detected intracellularly and on transfected Vero cell surfaces. These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients. These results suggest that SARS CoV-2 is able to spread from cell-to-cell much more efficiently than SARS-CoV effectively avoiding extracellular neutralizing antibodies. A systematic screening of several drugs including cardiac glycosides and kinase inhibitors and inhibitors of HIV entry revealed that only the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited Sn and So-mediated cell fusion with complete inhibition at a 10 muM concentration. In silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting Sn and So-mediated membrane fusion. Also, it is possible that nelfinavir may act to inhibit S proteolytic processing within cells. These results warrant further investigations of the potential of nelfinavir mesylate to inhibit virus spread at early times after SARS CoV-2 symptoms appear. This article is protected by copyright. All rights reserved.","J Med Virol","Musarrat, Farhana","Chouljenko, Vladimir","Dahal, Achyut","Nabi, Rafiq","Chouljenko, Tamara","Jois, Seetharama D","Kousoulas, Konstantin G","32374457"],"abstract":["SARS coronavirus-2 (SARS CoV-2) is the causative agent of the Coronavirus Disease-2019 (COVID-19) pandemic. Coronaviruses enter cells via fusion of the viral envelope with the plasma membrane and/or via fusion of the viral envelope with endosomal membranes after virion endocytosis. The Spike (S) glycoprotein is a major determinant of virus infectivity. Herein, we show that transient expression of the SARS CoV-2 S glycoprotein in Vero cells caused extensive cell fusion (formation of syncytia) in comparison to limited cell fusion caused by the SARS CoV S glycoprotein. Both S glycoproteins were detected intracellularly and on transfected Vero cell surfaces. These results are in agreement with published pathology observations of extensive syncytial formation in lung tissues of COVID-19 patients. These results suggest that SARS CoV-2 is able to spread from cell-to-cell much more efficiently than SARS-CoV effectively avoiding extracellular neutralizing antibodies. A systematic screening of several drugs including cardiac glycosides and kinase inhibitors and inhibitors of HIV entry revealed that only the FDA approved HIV-protease inhibitor, nelfinavir mesylate (Viracept) drastically inhibited Sn and So-mediated cell fusion with complete inhibition at a 10 muM concentration. In silico docking experiments suggested the possibility that nelfinavir may bind inside the S trimer structure, proximal to the S2 amino terminus directly inhibiting Sn and So-mediated membrane fusion. Also, it is possible that nelfinavir may act to inhibit S proteolytic processing within cells. These results warrant further investigations of the potential of nelfinavir mesylate to inhibit virus spread at early times after SARS CoV-2 symptoms appear. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Musarrat, Farhana","Chouljenko, Vladimir","Dahal, Achyut","Nabi, Rafiq","Chouljenko, Tamara","Jois, Seetharama D","Kousoulas, Konstantin G"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374457","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1002/jmv.25985","keywords":["antiviral agents","cell fusion","cellular effect","coronavirus","entry inhibitors","fusion protein","glycoproteins","infection","sars coronavirus","virus classification"],"e_drugs":["Tin","Nelfinavir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496346095616,"score":151.75296},{"pmid":32478895,"title":"Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.","text":["Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.","BACKGROUND: The objective of this study was to identify a subgroup of patients with head and neck squamous cell carcinoma (HNSCC) who might be suitable for hypofractionated radiotherapy (RT-hypo) during the COVID-19 pandemic. METHODS: HNSCC cases (oropharynx/larynx/hypopharynx) treated with definitive RT-hypo (60 Gy in 25 fractions over 5 weeks), moderately accelerated radiotherapy (RT-acc) alone (70 Gy in 35 fractions over 6 weeks), or concurrent chemoradiotherapy (CCRT) during 2005-2017 were included. Locoregional control (LRC) and distant control (DC) after RT-hypo, RT-acc, and CCRT were compared for various subgroups. RESULTS: The study identified 994 human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma cases (with 61, 254, and 679 receiving RT-hypo, RT-acc, and CCRT, respectively) and 1045 HPV- HNSCC cases (with 263, 451, and 331 receiving RT-hypo, RT-acc, and CCRT, respectively). The CCRT cohort had higher T/N categories, whereas the radiotherapy-alone patients were older. The median follow-up was 4.6 years. RT-hypo, RT-acc, and CCRT produced comparable 3-year LRC and DC for HPV+ T1-2N0-N2a disease (seventh edition of the TNM system [TNM-7]; LRC, 94%, 100%, and 94%; P = .769; DC, 94%, 100%, and 94%; P = .272), T1-T2N2b disease (LRC, 90%, 94%, and 97%; P = .445; DC, 100%, 96%, and 95%; P = .697), and T1-2N2c/T3N0-N2c disease (LRC, 89%, 93%, and 95%; P = .494; DC, 89%, 90%, and 87%; P = .838). Although LRC was also similar for T4/N3 disease (78%, 84%, and 88%; P = .677), DC was significantly lower with RT-hypo or RT-acc versus CCRT (67%, 65%, and 87%; P = .005). For HPV- HNSCC, 3-year LRC and DC were similar with RT-hypo, RT-acc, and CCRT in stages I and II (LRC, 85%, 89%, and 100%; P = .320; DC, 99%, 98%, and 100%; P = .446); however, RT-hypo and RT-acc had significantly lower LRC in stage III (76%, 69%, and 91%; P = .006), whereas DC rates were similar (92%, 85%, and 90%; P = .410). Lower LRC in stage III predominated in patients with laryngeal squamous cell carcinoma receiving RT-acc (62%) but not RT-hypo (80%) or CCRT (92%; RT-hypo vs CCRT: P = .270; RT-acc vs CCRT: P = .004). CCRT had numerically higher LRC in comparison with RT-hypo or RT-acc in stage IV (73%, 65%, and 66%; P = .336). CONCLUSIONS: It is proposed that RT-hypo be considered in place of CCRT for HPV+ T1-T3N0-N2c (TNM-7) HNSCCs, HPV- T1-T2N0 HNSCCs, and select stage III HNSCCs during the COVID-19 outbreak.","Cancer","Huang, Shao Hui","O'Sullivan, Brian","Su, Jie","Ringash, Jolie","Bratman, Scott V","Kim, John","Hosni, Ali","Bayley, Andrew","Cho, John","Giuliani, Meredith","Hope, Andrew","Spreafico, Anna","Hansen, Aaron R","Siu, Lillian L","Gilbert, Ralph","Irish, Jonathan C","Goldstein, David","de Almeida, John","Tong, Li","Xu, Wei","Waldron, John","32478895"],"abstract":["BACKGROUND: The objective of this study was to identify a subgroup of patients with head and neck squamous cell carcinoma (HNSCC) who might be suitable for hypofractionated radiotherapy (RT-hypo) during the COVID-19 pandemic. METHODS: HNSCC cases (oropharynx/larynx/hypopharynx) treated with definitive RT-hypo (60 Gy in 25 fractions over 5 weeks), moderately accelerated radiotherapy (RT-acc) alone (70 Gy in 35 fractions over 6 weeks), or concurrent chemoradiotherapy (CCRT) during 2005-2017 were included. Locoregional control (LRC) and distant control (DC) after RT-hypo, RT-acc, and CCRT were compared for various subgroups. RESULTS: The study identified 994 human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma cases (with 61, 254, and 679 receiving RT-hypo, RT-acc, and CCRT, respectively) and 1045 HPV- HNSCC cases (with 263, 451, and 331 receiving RT-hypo, RT-acc, and CCRT, respectively). The CCRT cohort had higher T/N categories, whereas the radiotherapy-alone patients were older. The median follow-up was 4.6 years. RT-hypo, RT-acc, and CCRT produced comparable 3-year LRC and DC for HPV+ T1-2N0-N2a disease (seventh edition of the TNM system [TNM-7]; LRC, 94%, 100%, and 94%; P = .769; DC, 94%, 100%, and 94%; P = .272), T1-T2N2b disease (LRC, 90%, 94%, and 97%; P = .445; DC, 100%, 96%, and 95%; P = .697), and T1-2N2c/T3N0-N2c disease (LRC, 89%, 93%, and 95%; P = .494; DC, 89%, 90%, and 87%; P = .838). Although LRC was also similar for T4/N3 disease (78%, 84%, and 88%; P = .677), DC was significantly lower with RT-hypo or RT-acc versus CCRT (67%, 65%, and 87%; P = .005). For HPV- HNSCC, 3-year LRC and DC were similar with RT-hypo, RT-acc, and CCRT in stages I and II (LRC, 85%, 89%, and 100%; P = .320; DC, 99%, 98%, and 100%; P = .446); however, RT-hypo and RT-acc had significantly lower LRC in stage III (76%, 69%, and 91%; P = .006), whereas DC rates were similar (92%, 85%, and 90%; P = .410). Lower LRC in stage III predominated in patients with laryngeal squamous cell carcinoma receiving RT-acc (62%) but not RT-hypo (80%) or CCRT (92%; RT-hypo vs CCRT: P = .270; RT-acc vs CCRT: P = .004). CCRT had numerically higher LRC in comparison with RT-hypo or RT-acc in stage IV (73%, 65%, and 66%; P = .336). CONCLUSIONS: It is proposed that RT-hypo be considered in place of CCRT for HPV+ T1-T3N0-N2c (TNM-7) HNSCCs, HPV- T1-T2N0 HNSCCs, and select stage III HNSCCs during the COVID-19 outbreak."],"journal":"Cancer","authors":["Huang, Shao Hui","O'Sullivan, Brian","Su, Jie","Ringash, Jolie","Bratman, Scott V","Kim, John","Hosni, Ali","Bayley, Andrew","Cho, John","Giuliani, Meredith","Hope, Andrew","Spreafico, Anna","Hansen, Aaron R","Siu, Lillian L","Gilbert, Ralph","Irish, Jonathan C","Goldstein, David","de Almeida, John","Tong, Li","Xu, Wei","Waldron, John"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32478895","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/cncr.32968","keywords":["covid-19","altered fractionation","chemoradiotherapy","head and neck cancer","hypofractionation","outcome","radiotherapy"],"topics":["Prevention"],"weight":1,"_version_":1668437835204526080,"score":142.15677},{"pmid":32311094,"title":"Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread.","text":["Distinct Viral Clades of SARS-CoV-2: Implications for Modeling of Viral Spread.","Distinct viral clades have a likely impact on COVID-19 pathogenesis and spread. Sequence analysis from 2310 viral isolates from Nexstrain reveals that residue at 614 of the viral spike protein is changed from a putative ancestral aspartic acid (D) to a glycine (G) between two viral clades. The G strain is predominantly on the East Coast of the United States, and the D strain is predominantly on the West Coast. This mutation of the SARS-CoV-2 S protein spike is conserved in coronaviruses. Point mutations in a murine coronavirus spike protein can result in increased virulence through instability of the viral machinery and altered viral to cell membrane fusion. This observation may partially explain the discrepancy in predicted deaths from COVID-19 between the East Coast and West Coast, and possibly explain that other factors aside from social distance, such as competition between two strains of differing virulence, may be at play. This article is protected by copyright. All rights reserved.","J Med Virol","Brufsky, Adam","32311094"],"abstract":["Distinct viral clades have a likely impact on COVID-19 pathogenesis and spread. Sequence analysis from 2310 viral isolates from Nexstrain reveals that residue at 614 of the viral spike protein is changed from a putative ancestral aspartic acid (D) to a glycine (G) between two viral clades. The G strain is predominantly on the East Coast of the United States, and the D strain is predominantly on the West Coast. This mutation of the SARS-CoV-2 S protein spike is conserved in coronaviruses. Point mutations in a murine coronavirus spike protein can result in increased virulence through instability of the viral machinery and altered viral to cell membrane fusion. This observation may partially explain the discrepancy in predicted deaths from COVID-19 between the East Coast and West Coast, and possibly explain that other factors aside from social distance, such as competition between two strains of differing virulence, may be at play. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Brufsky, Adam"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311094","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25902","keywords":["sars coronavirus","virulence","virus classification"],"locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Aspartic Acid","Glycine"],"topics":["Mechanism","Prevention"],"weight":1,"_version_":1666138491222753280,"score":136.49185},{"pmid":32432519,"title":"Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease (COVID-19)?","text":["Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease (COVID-19)?","Rotating and permanent night shiftwork schedules typically result in acute and sometimes chronic sleep deprivation plus acute and sometimes chronic disruption of the circadian time structure. Immune system processes and functionalities are organized as circadian rhythms, and they are also strongly influenced by sleep status. Sleep is a vital behavioral state of living beings and a modulator of immune function and responsiveness. Shiftworkers show increased risk for developing viral infections due to possible compromise of both innate and acquired immunity responses. Short sleep and sleep loss, common consequences of shiftwork, are associated with altered integrity of the immune system. We discuss the possible excess risk for COVID-19 infection in the context of the common conditions among shiftworkers, including nurses, doctors, and first responders, among others of high exposure to the contagion, of sleep imbalance and circadian disruption.Abbreviations: ACE2: Angiotensin-converting enzyme 2; APC: Antigen-presenting cells; CCL: Chemokine (C-C motif) ligand; CD(+): Adhesion molecule expression; COVID-19: 2019 coronavirus disease; DCs: Dendritic cells; GH: Growth hormone; HPA: Hypothalamic-pituitary-adrenal; HSF: Heat shock factor; HSP70: Heat shock protein 70; HSP90: Heat shock protein 90; IL: Interleukin; INFgamma: Interferon-gamma; LT/LB: T/B lymphocytes; MHC: Major histocompatibility complex; NK: Natural killer; RAAS: renin-angiotensin-aldosterone system; SARS: Severe acute respiratory syndrome; SCN: Suprachiasmatic nucleus;SD: Sleep deprivation; SNS: Sympathetic nervous system; Th1/Th2: T helper lymphocytes 1/2; TLR2/TLR4: Toll-like receptor 2/4; TNF-alpha: Tumor necrosis factor alpha; VEGF: Vascular endothelial growth factor.","Chronobiol Int","Silva, Flavia Rodrigues da","Guerreiro, Renato de Carvalho","Andrade, Henrique de Araujo","Stieler, Eduardo","Silva, Andressa","de Mello, Marco Tulio","32432519"],"abstract":["Rotating and permanent night shiftwork schedules typically result in acute and sometimes chronic sleep deprivation plus acute and sometimes chronic disruption of the circadian time structure. Immune system processes and functionalities are organized as circadian rhythms, and they are also strongly influenced by sleep status. Sleep is a vital behavioral state of living beings and a modulator of immune function and responsiveness. Shiftworkers show increased risk for developing viral infections due to possible compromise of both innate and acquired immunity responses. Short sleep and sleep loss, common consequences of shiftwork, are associated with altered integrity of the immune system. We discuss the possible excess risk for COVID-19 infection in the context of the common conditions among shiftworkers, including nurses, doctors, and first responders, among others of high exposure to the contagion, of sleep imbalance and circadian disruption.Abbreviations: ACE2: Angiotensin-converting enzyme 2; APC: Antigen-presenting cells; CCL: Chemokine (C-C motif) ligand; CD(+): Adhesion molecule expression; COVID-19: 2019 coronavirus disease; DCs: Dendritic cells; GH: Growth hormone; HPA: Hypothalamic-pituitary-adrenal; HSF: Heat shock factor; HSP70: Heat shock protein 70; HSP90: Heat shock protein 90; IL: Interleukin; INFgamma: Interferon-gamma; LT/LB: T/B lymphocytes; MHC: Major histocompatibility complex; NK: Natural killer; RAAS: renin-angiotensin-aldosterone system; SARS: Severe acute respiratory syndrome; SCN: Suprachiasmatic nucleus;SD: Sleep deprivation; SNS: Sympathetic nervous system; Th1/Th2: T helper lymphocytes 1/2; TLR2/TLR4: Toll-like receptor 2/4; TNF-alpha: Tumor necrosis factor alpha; VEGF: Vascular endothelial growth factor."],"journal":"Chronobiol Int","authors":["Silva, Flavia Rodrigues da","Guerreiro, Renato de Carvalho","Andrade, Henrique de Araujo","Stieler, Eduardo","Silva, Andressa","de Mello, Marco Tulio"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32432519","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/07420528.2020.1756841","keywords":["covid-19","circadian disruption","immune system","shiftwork","sleep deprivation"],"locations":["circadian","circadian"],"topics":["Prevention"],"weight":1,"_version_":1667342288420864000,"score":132.99252},{"pmid":32497323,"title":"Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.","text":["Increasing Host Cellular Receptor-Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV (or SARS-CoV-2) Infection.","The ongoing outbreak of a new coronavirus (2019-nCoV, or SARS-CoV-2) has caused an epidemic of the acute respiratory syndrome known as COVID-19 in humans. SARS-CoV-2 rapidly spread to multiple regions of China and multiple other countries, posing a serious threat to public health. The spike (S) proteins of SARS-CoV-1 and SARS-CoV-2 may use the same host cellular receptor, angiotensin-converting enzyme 2 (ACE2), for entering into host cells. The affinity between ACE2 and the SARS-CoV-2 S protein is much higher than that of ACE2 binding to the SARS-CoV S protein, explaining why SARS-CoV-2 seems to be more readily transmitted from the human to human. Here, we report that ACE2 can be significantly upregulated after infection of various viruses, including SARS-CoV-1 and SARS-CoV-2, or by the stimulation with inflammatory cytokines such as interferons. We propose that SARS-CoV-2 may positively induce its cellular entry receptor, ACE2, to accelerate its replication and spread; high inflammatory cytokine levels increase ACE2 expression and act as high-risk factors for developing COVID-19, and the infection of other viruses may increase the risk of SARS-CoV-2 infection. Therefore, drugs targeting ACE2 may be developed for the future emerging infectious diseases caused by this cluster of coronaviruses. This article is protected by copyright. All rights reserved.","J Med Virol","Zhuang, Meng-Wei","Cheng, Yun","Zhang, Jing","Jiang, Xue-Mei","Wang, Li","Deng, Jian","Wang, Pei-Hui","32497323"],"abstract":["The ongoing outbreak of a new coronavirus (2019-nCoV, or SARS-CoV-2) has caused an epidemic of the acute respiratory syndrome known as COVID-19 in humans. SARS-CoV-2 rapidly spread to multiple regions of China and multiple other countries, posing a serious threat to public health. The spike (S) proteins of SARS-CoV-1 and SARS-CoV-2 may use the same host cellular receptor, angiotensin-converting enzyme 2 (ACE2), for entering into host cells. The affinity between ACE2 and the SARS-CoV-2 S protein is much higher than that of ACE2 binding to the SARS-CoV S protein, explaining why SARS-CoV-2 seems to be more readily transmitted from the human to human. Here, we report that ACE2 can be significantly upregulated after infection of various viruses, including SARS-CoV-1 and SARS-CoV-2, or by the stimulation with inflammatory cytokines such as interferons. We propose that SARS-CoV-2 may positively induce its cellular entry receptor, ACE2, to accelerate its replication and spread; high inflammatory cytokine levels increase ACE2 expression and act as high-risk factors for developing COVID-19, and the infection of other viruses may increase the risk of SARS-CoV-2 infection. Therefore, drugs targeting ACE2 may be developed for the future emerging infectious diseases caused by this cluster of coronaviruses. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Zhuang, Meng-Wei","Cheng, Yun","Zhang, Jing","Jiang, Xue-Mei","Wang, Li","Deng, Jian","Wang, Pei-Hui"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32497323","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26139","keywords":["2019-ncov","ace2","covid-19","ifn","isg","sars-cov-2"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668712823848435712,"score":122.54467}]}